Literature DB >> 28986313

Impact of Clostridium difficile infection caused by the NAP1/RT027 strain on severity and recurrence during an outbreak and transition to endemicity in a Mexican tertiary care center.

Karla María Tamez-Torres1, Pedro Torres-González1, Francisco Leal-Vega1, Ariana García-Alderete1, Norma Irene López García1, Raquel Mendoza-Aguilar1, Arturo Galindo-Fraga2, Miriam Bobadilla-Del Valle1, Alfredo Ponce de León1, José Sifuentes-Osornio3.   

Abstract

OBJECTIVES: To describe the clinical characteristics, outcomes, and factors associated with Clostridium difficile infection (CDI) due to ribotype 027 (RT027) and recurrence, including an outbreak period, with transition to endemicity.
METHODS: A case-control study was performed. Clinical and demographic data were collected for patients with CDI during the period January 2008 to December 2015. Ribotyping of the isolates and PCR for toxin A, B, and binary were performed.
RESULTS: Among 324 episodes of CDI, 27.7% were caused by RT027. Previous fluoroquinolone use (odds ratio (OR) 1.79, 95% confidence interval (CI) 1.01-3.17), previous gastrointestinal endoscopy (OR 2.17, 95% CI 1.29-3.65), chemotherapy (OR 0.43, 95% CI 0.19-0.95), and total enteral nutrition (OR 0.42, 95% CI 0.18-0.97) were associated with RT027. Age >65 years (OR 2.05, 95% CI 1.02-4.10), severe initial episode (OR 3.35, 95% CI 1.60-6.15), previous proton pump inhibitor use (OR 2.34, 95% CI 1.15-4.74), and continued fluoroquinolones (OR 3.08, 95% CI 1.11-8.51) were associated with recurrence. Among the non-RT027, 59.8% were not assigned by the ribotyping database and 50.7% presented binary toxin.
CONCLUSIONS: In this population, CDI due to the RT027 strain was not associated with poorer outcomes. This study reinforces the importance of avoiding fluoroquinolones and PPIs to prevent recurrences. The presence of virulence factors among non-RT027 C. difficile strains underscores the importance of performing molecular epidemiology surveillance.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Molecular epidemiology; Recurrence; Ribotyping

Mesh:

Substances:

Year:  2017        PMID: 28986313     DOI: 10.1016/j.ijid.2017.09.022

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

1.  Design and characterization of a novel lytic protein against Clostridium difficile.

Authors:  Meng Wang; Zifeng Deng; Yanmei Li; Yi Ma; Jufang Wang
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-14       Impact factor: 5.560

2.  Factors associated with an outbreak of hospital-onset, healthcare facility-associated Clostridium difficile infection (HO-HCFA CDI) in a Mexican tertiary care hospital: A case-control study.

Authors:  Eric Ochoa-Hein; José Sifuentes-Osornio; Alfredo Ponce de León-Garduño; Pedro Torres-González; Víctor Granados-García; Arturo Galindo-Fraga
Journal:  PLoS One       Date:  2018-05-29       Impact factor: 3.240

3.  Production of p-cresol by Decarboxylation of p-HPA by All Five Lineages of Clostridioides difficile Provides a Growth Advantage.

Authors:  Mark A Harrison; Harparkash Kaur; Brendan W Wren; Lisa F Dawson
Journal:  Front Cell Infect Microbiol       Date:  2021-10-29       Impact factor: 5.293

4.  Implementation of control measures against an outbreak due to Clostridioides difficile producing toxin B in a tertiary hospital in Mexico.

Authors:  Oscar Sosa-Hernández; Bernardina Matías-Téllez; Juana González-Martínez; Rocio Juárez-Vargas; Norma Elizabeth González-González; Abril Estrada-Hernández; Monserrat Ruíz-Santana; Juan Carlos Bravata-Alcántara; Juan Manuel Bello-López
Journal:  J Prev Med Hyg       Date:  2021-07-30

5.  Low-toxin Clostridioides difficile RT027 strains exhibit robust virulence.

Authors:  Farhan Anwar; Bryan Angelo P Roxas; Kareem W Shehab; Neil M Ampel; V K Viswanathan; Gayatri Vedantam
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.